MASAŘÍK, Michal, Jiří SOCHOR, Ondřej ZÍTKA, David HYNEK, Soňa KŘÍŽKOVÁ, Marie STIBOROVÁ, Tomáš ECKSCHLAGER, Vojtěch ADAM a René KIZEK. Association of PSA level with thiols content in patients with prostate carcinoma. In 15th International Symposium on Molecular Medicine. 2012. ISSN 1107-3756.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Association of PSA level with thiols content in patients with prostate carcinoma
Autoři MASAŘÍK, Michal, Jiří SOCHOR, Ondřej ZÍTKA, David HYNEK, Soňa KŘÍŽKOVÁ, Marie STIBOROVÁ, Tomáš ECKSCHLAGER, Vojtěch ADAM a René KIZEK.
Vydání 15th International Symposium on Molecular Medicine, 2012.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Obor 10600 1.6 Biological sciences
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 1.957
Organizační jednotka Lékařská fakulta
ISSN 1107-3756
UT WoS 000310651600170
Klíčová slova anglicky PSA; prostate cancer; glutathione
Změnil Změnila: Mgr. Martina Raudenská, Ph.D., učo 42700. Změněno: 17. 10. 2012 11:26.
Anotace
To detect proste carcinoma, prostatic specific antigen (PSA) is mostly used. However, diagnostics of this tumour disease can become more precise using other types of molecules. In this study, we aimed at detennination of reduced (GSH) and oxidized (GSSG) glutathione, and its ratio, and level of metallothionein in blood of patients with prostate carcinoma. The obtained results were correlated with PSA levels determined in blood of patients. Analyses were petformed in 35 patients with prostate cancer at the age of 54 to 79 years with an average of 66 years and in 8 healthy subjects, who formed the control group. The correlation between PSA and GSH/GSSG reached R2=0.378. The value of PSA and metallothionein content was correlated with R2 = 0.589. However, there were observed large differences between the values of the ratio of GSH and GSSG, which were significantly (P<0.0 1) higher in the control group than in the group of patients with prostate cancer. Also, differences in content between metallothionein control group and a group of patients were highly significant (P<0.01).
VytisknoutZobrazeno: 27. 7. 2024 14:29